It’s almost time for the FDA to make a decision on mavacamten, the myosin inhibitor at the center of Bristol Myers Squibb’s $13 billion MyoKardia buyout. With a Jan. 28 PDUFA date looming, the pharma giant is now taking the wraps off some long-term data it hopes will bolster the drug’s case for approval.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,